What's News: Business & Finance -- WSJ

Features Dow Jones Newswires

This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (December 20, 2017).

Continue Reading Below

The FDA approved the first therapy in the U.S. to target a disease caused by a single faulty gene, clearing for sale a Spark treatment for vision loss.

Humana and two private-equity firms confirmed they plan to buy Kindred, and Tenet said it is exploring a sale of Conifer.

A Senate panel rejected Trump's pick to run the Ex-Im Bank, escalating a GOP rift over the agency.

BHP is threatening to leave a coal industry group and the U.S. Chamber of Commerce over disagreements on climate policy.

German authorities accused Facebook of abusing its market dominance in its collection of user data.

Continue Reading Below

Regulators would have more discretion to decide which banks to target for stricter oversight under a bill passed by the House.

The eight largest and most complex U.S. banks avoided a major rebuke on their latest "living will" plans.

Declining tech shares dragged down U.S. stocks. The Dow shed 37.45 points to finish at 24754.75.

U.S. housing starts in November hit their highest level in over a year, driven by gains in the South and West.

A Chinese industry group has told fund raters to stop publicizing the sizes of money-market mutual funds.

A cryptocurrency exchange in South Korea collapsed after being hit by a second cyberattack in eight months.

(END) Dow Jones Newswires

December 20, 2017 02:47 ET (07:47 GMT)